Rapalink-1 reveals an mTOR- and p53-regulated transcriptional program in Neuro-2a cells
- 1Department of Biological Sciences, Clemson University, Clemson, SC 29634, USA
- 2Department of Biochemistry and Genetics, Clemson University, Clemson, SC 29634, USA
- 3Institute for Human Genetics, Clemson University, Greenwood, SC 29646, USA
Abstract
The mammalian target of rapamycin (mTOR) is the catalytic subunit of two exclusive complexes referred to as mTORC1 and mTORC2. The mTORCs phosphorylate different substrates and control different cellular processes. Inhibitors of mTORC1 include rapamycin analogs (rapalogs) that are useful in many clinical settings. However, they have failed in cancer trials potentially due to resistance mechanisms and incomplete inhibition of mTORC1 phosphorylation of select substrates. The rapamycin sensitivity of mTORC1 substrates is likely encoded by the substrate's primary amino acid sequence determinants and the ability of substrates to fit into the catalytic region of the kinase super-complex. Thus, some mTORC1 substrates are unaffected by rapalogs. Second-generation ATP-binding pocket inhibitors are mTOR catalytic inhibitors that bind in an ATP-competitive manner. Torin1 is an exemplary second-generation mTOR inhibitor with superior inhibition of mTORC1 substrates, including 4EBP. However, these inhibitors fail to demonstrate selectivity between mTORC1 and mTORC2. Third-generation bisteric mTORC1 inhibitors are exemplified by Rapalink-1, which links a rapamycin moiety to the ATP-competitive inhibitor MLN-0128. Here, we report that Rapalink-1 inhibits three mTORC1 substrates, including 4EBP and Ulk1, which are rapamycin insensitive. To provide additional mechanistic insight into the Rapalink-1 mechanism of action, RNA sequencing of Neuro-2a cells treated with Rapalink-1 was performed. Rapalink-1 caused transcriptomic changes indicative of reductions in the mTOR pathway and brain development. Many transcripts contained a p53 binding site, and consistent with this finding, we also observed reduced levels of p53. These results confirm and expand upon the Rapalink-1 mechanism of action.
Related
- FERMT2 expression in human articular chondrocytes is regulated by hypoxia-associated transcriptional programs
- Multi-omic profiling reveals impaired luteal resolution and CHK2-regulated inflammation in ovarian aging
- Induction of hysteretic chromatin states by CRISPRa reveals locus-specific encoding of transcriptional memory
- Single-nucleus RNA sequencing in ischemic cardiomyopathy reveals common transcriptional profile underlying end-stage heart failure
- Mapping of CELF1–RNA interactions reveals post-transcriptional control of lens development
BibTeX
@article{nyarkoh2026rapalink1,
title = {{Rapalink-1 reveals an mTOR- and p53-regulated transcriptional program in Neuro-2a cells}},
author = {Joel Karikari Nyarkoh and Matthew Wolan and Eric Barrett and Aidan M. Sokolov and Rachel A. Lyman and Trudy F. C. Mackay and David M. Feliciano},
journal = {Biology Open},
year = {2026},
month = oct,
doi = {10.1242/bio.062902},
url = {https://doi.org/10.1242/bio.062902},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Rapalink-1 reveals an mTOR- and p53-regulated transcriptional program in Neuro-2a cells
AU - Joel Karikari Nyarkoh
AU - Matthew Wolan
AU - Eric Barrett
AU - Aidan M. Sokolov
AU - Rachel A. Lyman
AU - Trudy F. C. Mackay
AU - David M. Feliciano
PY - 2026
DA - 2026/10/22
JO - Biology Open
DO - 10.1242/bio.062902
UR - https://doi.org/10.1242/bio.062902
AB - The mammalian target of rapamycin (mTOR) is the catalytic subunit of two exclusive complexes referred to as mTORC1 and mTORC2. The mTORCs phosphorylate different substrates and control different cellular processes. Inhibitors of mTORC1 include rapamycin analogs (rapalogs) that are useful in many clinical settings. However, they have failed in cancer trials potentially due to resistance mechanisms and incomplete inhibition of mTORC1 phosphorylation of select substrates. The rapamycin sensitivity of mTORC1 substrates is likely encoded by the substrate's primary amino acid sequence determinants and the ability of substrates to fit into the catalytic region of the kinase super-complex. Thus, some mTORC1 substrates are unaffected by rapalogs. Second-generation ATP-binding pocket inhibitors are mTOR catalytic inhibitors that bind in an ATP-competitive manner. Torin1 is an exemplary second-generation mTOR inhibitor with superior inhibition of mTORC1 substrates, including 4EBP. However, these inhibitors fail to demonstrate selectivity between mTORC1 and mTORC2. Third-generation bisteric mTORC1 inhibitors are exemplified by Rapalink-1, which links a rapamycin moiety to the ATP-competitive inhibitor MLN-0128. Here, we report that Rapalink-1 inhibits three mTORC1 substrates, including 4EBP and Ulk1, which are rapamycin insensitive. To provide additional mechanistic insight into the Rapalink-1 mechanism of action, RNA sequencing of Neuro-2a cells treated with Rapalink-1 was performed. Rapalink-1 caused transcriptomic changes indicative of reductions in the mTOR pathway and brain development. Many transcripts contained a p53 binding site, and consistent with this finding, we also observed reduced levels of p53. These results confirm and expand upon the Rapalink-1 mechanism of action.
SN - 2046-6390
ER -